SEC filings and other documents

Nautilus is launching a disruptive proteomics platform targeting major drug development challenges.

New proteomics platform promises comprehensive, reproducible protein analysis with broad applications.

Voyager instrument and early access launch drive momentum; commercial ramp set for 2027.

Q3 2025 delivered scientific progress, lower expenses, and a strong cash runway through 2027.

Disruptive proteomics technology targets late 2026 launch, promising broad biomedical impact.

Comprehensive proteomics platform targets full launch next year, emphasizing broad-scale discovery.

Milestone quarter with public platform validation, strong demand, and reduced operating expenses.

Comprehensive proteomics platform targets late 2026 launch, promising transformative research impact.

Tau assay validation exceeded targets; expenses fell; cash runway extends through 2027.

Proteomics platform targets 90%-95% coverage, with launch delayed to late 2026 for technical refinement.

Launch delayed to late 2026; FY 2024 net loss up 11%; cash runway now through 2027.

Innovative proteomics platform targets 2025 launch, promising unmatched sensitivity and market impact.

Proteoform advances accelerate, broad-scale lags, cash runway extends to 2027, launch set for late 2025.

Comprehensive, high-sensitivity proteomics platform targets 2025 launch with robust financials.

Platform development advances, OpEx growth slows, and 2025 launch remains on track.